Bio­gen makes its move, an­nounc­ing a $7.3B deal for Rea­ta

Bio­gen and its new CEO are fi­nal­ly wad­ing in­to 2023’s M&A wave with a $7.3 bil­lion deal for Rea­ta Phar­ma­ceu­ti­cals, which just se­cured FDA ap­proval for a rare ge­net­ic dis­ease.

The biotech com­pa­ny will pay $172.50 per share in cash for Rea­ta, which re­cent­ly launched Skyclarys for Friedre­ich’s atax­ia in the US and is un­der­go­ing a Eu­ro­pean reg­u­la­to­ry re­view. Stifel an­a­lyst Paul Mat­teis said the deal’s price is “hefty, but not if Skyclarys can meet $1B in rev­enues.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER